STOCK TITAN

Dr Reddys Labs - RDY STOCK NEWS

Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.

Dr. Reddy's Laboratories (RDY) maintains its position as a global pharmaceutical innovator through strategic developments in generic medicines, biosimilars, and active pharmaceutical ingredients. This news hub provides investors and industry professionals with essential updates on corporate milestones, regulatory filings, and market expansions.

Access real-time information about earnings announcements, partnership agreements, and product pipeline advancements. Our curated collection features official press releases covering FDA approvals, manufacturing facility certifications, and therapeutic area breakthroughs in oncology and gastroenterology.

Monitor critical updates including patent litigation outcomes, emerging market entries, and sustainability initiatives. The repository serves as a reliable resource for understanding RDY's operational strategies and quality compliance across 75+ countries.

Bookmark this page for streamlined access to verified updates about Dr. Reddy's Laboratories. Check regularly for insights into biosimilar developments, API production innovations, and financial performance indicators shaping the global pharmaceutical landscape.

Rhea-AI Summary

Dr. Reddy's Laboratories announced the launch of Doxycycline Capsules, 40 mg in the U.S., a generic equivalent of ORACEA® approved by the USFDA. The capsules contain immediate-release and delayed-release pellets, each totaling 40 mg of anhydrous doxycycline. This launch is a significant development for Dr. Reddy's in the U.S. market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
Rhea-AI Summary
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) biosimilar in the UK for treating various cancers, following successful launches in India and other countries. The product is a potential treatment option for metastatic colorectal cancer, advanced lung, brain, renal, cervical, ovarian, and breast cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
Rhea-AI Summary
Dr. Reddy’s Laboratories Ltd. announced consolidated financial results for Q3FY24 and 9MFY24, with a 7% YoY revenue increase. The company reported a 58.5% gross margin for Q3FY24 and a 30.9% EBITDA margin for 9MFY24. Dr. Reddy’s Laboratories also highlighted key business developments and ESG achievements, positioning the company as a leader in the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
Rhea-AI Summary
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) has acquired MenoLabs® business, a leading women’s health and dietary supplement branded portfolio from Amyris, Inc. The acquisition includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause, along with the MenoLife® health tracker app. This deal will accelerate Dr. Reddy's growth in the women’s nutritional and wellness markets, complementing their U.S. self-care and wellness business portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Summary
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) has achieved significant milestones in sustainability and Environment Social and Governance (ESG) initiatives. The company has secured 'Gold Medal' status from the global sustainability ratings agency, EcoVadis, and is featured in the Dow Jones Sustainability World Index for 2023, marking its debut in the index. Dr. Reddy's also retains its place in the Dow Jones Sustainability Emerging Markets Index for the 8th consecutive year. It has become the first Indian pharma company to pledge towards an integrated plantation initiative covering 2,900 hectares by 2028 as part of the World Economic Forum's 1t.org.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
none
-
Rhea-AI Summary
Dr. Reddy's Laboratories SA (NYSE: RDY) and Coya Therapeutics, Inc. (NASDAQ: COYA) have entered into a development and license agreement for the commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). The agreement grants Dr. Reddy's the exclusive rights to commercialize COYA 302 in the United States, Canada, the European Union, and the United Kingdom. The agreement includes an upfront payment of USD 7.5 million to Coya, with additional milestone payments of up to USD 40 million and sales-based milestone payments of up to USD 677.25 million. Dr. Reddy's will also pay royalties based on a percentage of net sales of COYA 302 ranging from low to middle teens. The development of COYA 302 was a result of a research collaboration between Coya and Houston Methodist in the laboratory of Dr. Stanley Appel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
News
Rhea-AI Summary
Dr. Reddy’s Laboratories Ltd. announces its consolidated financial results for Q3 2023. Revenues increased by 9% YoY and 2% QoQ. Gross margin is 58.7%. SG&A expenses increased by 13% YoY and 6% QoQ. R&D expenses are 7.9% of revenues. EBITDA is 31.7% of revenues. Profit before Tax increased by 19% YoY and 4% QoQ. Profit after Tax increased by 33% YoY and 6% QoQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
-
Rhea-AI Summary
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced the launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a generic version of KOMBIGLYZE® XR tablets. The tablets are approved by the USFDA and come in strengths of 2.5 mg/1000 mg and 5 mg/500 mg and 5 mg/1000 mg. The company also provided a link to the full prescribing information, including a boxed warning for LACTIC ACIDOSIS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
News
Rhea-AI Summary
Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for Q2 2023. Revenues increased by 29% YoY and 7% QoQ. Gross margin improved to 58.7%. Profit before tax increased by 26% YoY and 39% QoQ. Profit after tax increased by 18% YoY and 46% QoQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
Rhea-AI Summary
Dr. Reddy’s Laboratories announced that its Biologics License Application for its proposed biosimilar rituximab candidate DRL_RI has been accepted for review by the USFDA, EMA, and MHRA. The company expects to bring more biosimilar products to meet patient needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
Dr Reddys Labs

NYSE:RDY

RDY Rankings

RDY Stock Data

2.33B
833.15M
15.04%
2.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
India
Hyderabad